Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2014; 20(37): 13466-13476
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13466
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13466
Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: Where are we now in the era of the next generation proteomics?
Jong-Min Park, Young-Min Han, Mi Kyung Chung, Eun-Hee Kim, Ki Baik Hahm, CHA Cancer Prevention Research Center, CHA University, Seoul 135-081, South Korea
Na Young Han, Hoo Keun Lee, Gachon University College of Pharmacy, Incheon 406-799, South Korea
Kwang Hyun Ko, Ki Baik Hahm, Digestive Disease Center, CHA University Bundang Medical Center, Seongnam 463-838, South Korea
Author contributions: Park JM and Han NY contributed equally to this manuscript; Park JM and Han NY performed the majority of the experiments; Han YM, Chung MK and Ko KH contributed new reagents or analytic tools; Lee HK, Kim EH, and Hahm KB designed the study; Park JM and Hahm KB analyzed the data and wrote the manuscript.
Supported by Grant from the Ministry of Education and Science Technology, 2010-0002052, Korea and JSPS Asian CORE Program, Japan
Correspondence to: Ki Baik Hahm, MD, PhD, Professor, CHA Cancer Prevention Research Center, CHA University, 605 Yeoksam 1-dong, Gangnam-gu, Seoul 135-081, South Korea. hahmkb@cha.ac.kr
Telephone: +82-2-34682869 Fax: +82-2-34682868
Received: December 27, 2013
Revised: March 10, 2014
Accepted: June 14, 2014
Published online: October 7, 2014
Revised: March 10, 2014
Accepted: June 14, 2014
Published online: October 7, 2014
Core Tip
Core tip: Our recent achievements in discovering biomarkers to predict cancer risk are introduced. Ultimately, models based on combinations of genotype and gene expression data referenced with clinical, biochemical, and serological data may permit the development of tools for individualized risk stratification and efficient treatment selection, as well as complete rescue from complications, including colitis-associated cancer, in the near future.